Anonymous
Guest
Anonymous
Guest
Lux capital, VC firm, Partner alongside James Woolsey, former Director of CIA under Clinton and advisor to Carter, Regan, Bush, and John McCain.
You can send him well-wishes at:
http://www.luxcapital.com/team/profile/jeff-kindler
Former Pfizer Inc. (PFE) Chairman and Chief Executive Jeff Kindler has joined venture-capital firm Lux Capital, to help work with the firm's portfolio companies and identify new health-care investment opportunities.
"With tremendous leadership experience in the health-care industry, Jeff has an appreciation for the intersection of novel science, product development and commercial transactions," said Robert Paull, managing partner at Lux Capital.
Mr. Kindler joined Pfizer as an executive vice president and general counsel in 2002 and was promoted to chairman in 2006. He left the pharmaceutical company in December 2010, citing fatigue, although investors also had grown anxious as a result of the stock's 36% decline under his leadership.
New York-based Lux Capital is an early investor in energy, technology, health-care and life sciences companies, funding developments from rapid vaccine discovery to nano-enabled drug delivery. Its investments include biopharmaceutical company Cerulean Pharma and Genocea Biosciences, which develops vaccines.
You can send him well-wishes at:
http://www.luxcapital.com/team/profile/jeff-kindler
Former Pfizer Inc. (PFE) Chairman and Chief Executive Jeff Kindler has joined venture-capital firm Lux Capital, to help work with the firm's portfolio companies and identify new health-care investment opportunities.
"With tremendous leadership experience in the health-care industry, Jeff has an appreciation for the intersection of novel science, product development and commercial transactions," said Robert Paull, managing partner at Lux Capital.
Mr. Kindler joined Pfizer as an executive vice president and general counsel in 2002 and was promoted to chairman in 2006. He left the pharmaceutical company in December 2010, citing fatigue, although investors also had grown anxious as a result of the stock's 36% decline under his leadership.
New York-based Lux Capital is an early investor in energy, technology, health-care and life sciences companies, funding developments from rapid vaccine discovery to nano-enabled drug delivery. Its investments include biopharmaceutical company Cerulean Pharma and Genocea Biosciences, which develops vaccines.